- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | HCW Biologics erhält FDA-Richtlinien für klinische Studie zu Krebsmedikament | 1 | Investing.com Deutsch | ||
| 02.10. | HCW Biologics Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 24.09. | HCW Biologics prices $1.5M private placement offering | 2 | Investing.com | ||
| 24.09. | HCW Biologics kündigt Privatplatzierung über 1,5 Millionen US-Dollar an | 1 | Investing.com Deutsch | ||
| 24.09. | HCW Biologics Inc.: HCW Biologics Announces Pricing of $1.5 Million Private Placement | 2 | GlobeNewswire (USA) | ||
| HCW BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 11.09. | Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AstraZeneca, GPCR Lead Clinical Trials | 1.497 | AFX News | NEW BRUNSWICK (dpa-AFX) - Biotech and healthcare saw regulatory approvals, strategic partnerships, M&A activity, and a steady stream of clinical trial updates driving investor attention.Notable... ► Artikel lesen | |
| 08.09. | HCW Biologics schließt Vertriebsvereinbarung mit Akron Biotech | 3 | Investing.com Deutsch | ||
| 08.09. | HCW Biologics signs distribution deal with Akron Biotech | 3 | Investing.com | ||
| 08.09. | HCW Biologics Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 08.09. | HCW Biologics Inc.: HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells | 3 | GlobeNewswire (USA) | ||
| 02.09. | HCW Biologics Inc.: HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment | 1 | GlobeNewswire (USA) | ||
| 28.08. | HCW Biologics Inc. - S-1/A, General form for registration of securities | 5 | SEC Filings | ||
| 25.08. | HCW Biologics Inc.: HCW Biologics' TGF-ß Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells | 1 | GlobeNewswire (USA) | ||
| 20.08. | HCW Biologics Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 14.08. | HCW Biologics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | HCW Biologics Inc.: HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results | 433 | GlobeNewswire (Europe) | MIRAMAR, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative... ► Artikel lesen | |
| 14.08. | HCW Biologics Inc. - 10-Q/A, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.07. | HCW Biologics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 29.07. | HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering | 620 | GlobeNewswire (Europe) | MIRAMAR, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion... ► Artikel lesen |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CELLECTAR BIOSCIENCES | 1,450 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,196 | -2,14 % | Redwood AI Corp.: Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph Oncology Platform | CALGARY, AB AND VANCOUVER, BC / ACCESS Newswire / September 22, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco") and Redwood AI Corp. (CSE:AIRX)(OTCQB:RDWCF)(Frankfurt:Y0N... ► Artikel lesen | |
| CEL-SCI | 1,840 | -8,00 % | CEL-SCI Corporation: Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients | Peer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,447 | +1,13 % | Moleculin Biotech, Inc.: Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit | ||
| PDS BIOTECHNOLOGY | 1,190 | -4,03 % | PDS Biotechnology Corp - 8-K, Current Report | ||
| LISATA THERAPEUTICS | 0,935 | 0,00 % | Lisata Therapeutics, Inc.: Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly | Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks... ► Artikel lesen | |
| GEOVAX LABS | 0,285 | +1,25 % | EQS-News: GeoVax, Inc.: GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026 | EQS-News: GeoVax, Inc.
/ Key word(s): Science
GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026 06.10.2026 / 14:37... ► Artikel lesen | |
| COCRYSTAL | 0,925 | +1,09 % | H.C. Wainwright reiterates Cocrystal Pharma stock rating at buy | ||
| GOSSAMER BIO | 8,216 | 0,00 % | XFRA 4GB0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| DECOY THERAPEUTICS | 1,470 | 0,00 % | Decoy Therapeutics Inc. - S-1, General form for registration of securities | ||
| JASPER THERAPEUTICS | 0,570 | 0,00 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants | REDWOOD CITY, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) ("Jasper" or the "Company"), a clinical stage biotechnology company focused on the design and development... ► Artikel lesen | |
| CHEMOMAB THERAPEUTICS | 1,370 | -0,72 % | Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer | ||
| VISTAGEN THERAPEUTICS | 0,236 | 0,00 % | Vistagen Therapeutics, Inc. - 8-K, Current Report | ||
| IN8BIO | 1,170 | -4,10 % | IN8bio, Inc: IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| METAVIA | 1,410 | 0,00 % | MetaVia Inc.: MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction | Tissue Distribution Study Shows Highest Exposure in Adipose Tissue and Prolonged Retention Consistent with Once-Weekly Dosing Findings Provide Mechanistic Support... ► Artikel lesen |
HCW BIOLOGICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,610 Euro und damit +0,62 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HCW BIOLOGICS INC finden Sie auf Wallstreet Online.